StatLab Medical Products acquires CellPath Ltd.


StatLab Medical Products (StatLab), an Audax Private Equity and Linden Capital Partners portfolio company and a leading developer and manufacturer of medical diagnostic supplies and equipment, today announced that it has acquired CellPath Ltd. (CellPath), a UK-based manufacturer and supplier of products and services focused on the histology and cytology markets. This addition of new manufacturing capabilities and established UK customer base both strengthens the core business and positions StatLab for international growth and market expansion.

Based in the UK, CellPath was founded in 1969 by Peter Webber as a histology consumables company known as Bethlehem Instruments, and quickly expanded into equipment. Today, CellPath is an established market leader in Europe, providing key products and services to both the cytology and histology market segments. With this acquisition, StatLab expands its reach into Europe, adds key injection molding manufacturing capabilities, and acquires proprietary products including the CellNass archiving service.

We have long respected CellPath for their well-earned reputation of delivering innovative products that solve problems for labs, and are proud to welcome them to the StatLab family of brands, Now paired with the strategic acquisition of UK-based equipment manufacturer Pyramid Innovation in 2021, CellPath’s established European market position and complementary portfolio will empower meaningful international growth in the histology sector.”

– Mike Karsonovich, CEO of StatLab.


StatLab is an excellent fit for us; their US market access and business infrastructure will help jointly expand customer access to products and services as a global market leader. We also appreciate their leadership commitment to ensure we maintain the high levels of service and quality that our family’s business is known for as we partner as one organization.”

– CellPath Joint Managing Director Philip Webber, along with his brother Paul.

CellPath will continue operating in the same locations and under the existing leadership structure to prevent any business disruption.


Next Post

AtriCure Announces Treatment of First Patient in HEAL-IST Clinical Trial

AtriCure, Inc. a leading innovator of surgical therapies and treatments for atrial fibrillation (AF), atrial appendage (AAG), as well as postoperative pain management, today announced that the first patient has been treated in the HEAL-IST™ trial (NCT 05280093). The first patient was treated by Drs Mark LaMeir and Carlo de Asmundis […]